International Nuclear Information System (INIS) Most of the activities described are ongoing the results and conclusions described may change as the work progresses. This monthly report describes activities performed in support of Cassini fueled-clad production and studies related to the use of in radioisotope power systems carried out for the Office of Special Applications of the US Department of Energy (DOE) by Los Alamos National Laboratory (LANL). Monthly progress report: Heat source technology programĮnergy Technology Data Exchange (ETDEWEB) However, improvements in secondary clinical and MRI outcome measures suggest that this treatment regimen may have a beneficial effect in progressive MS. Monthly methylprednisolone pulse treatment was safe, but had no effect on the primary outcome. Adverse events were well-known side effects to methylprednisolone. We found no change in the CSF concentration of osteopontin, but we observed significant improvement in clinical scores, MTR, DTI and some secondary CSF outcome measures. Secondary outcomes were other CSF biomarkers of inflammation, axonal damage and demyelination clinical scores magnetic resonance imaging measures of disease activity, magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI) motor evoked potentials and bone density scans. Primary outcome was changes in CSF concentrations of osteopontin. In this open-label phase 2A study, 15 primary progressive and 15 secondary progressive MS patients received oral methylprednisolone pulse treatment for 60 weeks. To evaluate the effect of monthly oral methylprednisolone pulse treatment on intrathecal inflammation in progressive MS. Phase 2 studies with cerebrospinal fluid (CSF) biomarker outcomes may be well suited for the initial evaluation of efficacious treatments. There is a large unmet need for treatments for patients with progressive multiple sclerosis (MS). Ratzer, Rikke Iversen, Pernille Börnsen, Lars Dyrby, Tim B Romme Christensen, Jeppe Ammitzbøll, Cecilie Madsen, Camilla Gøbel Garde, Ellen Lyksborg, Mark Andersen, Birgit Hyldstrup, Lars Sørensen, Per Soelberg Siebner, Hartwig R Sellebjerg, Finn Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. CONCLUSION: Monthly methylprednisolone pulse treatment was safe, but had. no change in the CSF concentration of osteopontin, but we observed significant improvement in clinical scores, MTR, DTI and some secondary CSF outcome measures. METHODS: In this open-label phase 2A study, 15 primary progressive and 15 secondary progressive MS patients received oral methylprednisolone pulse treatment for 60 weeks. methylprednisolone pulse treatment on intrathecal inflammation in progressive MS. OBJECTIVE: To evaluate the effect of monthly oral. Ratzer, Rikke Iversen, Pernille Börnsen, LarsīACKGROUND: There is a large unmet need for treatments for patients with progressive multiple sclerosis (MS). Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis The required shuttle support equipment, launch and flight operations techniques, development program, and cost package are also defined. This 100 percent capture is achieved without use of kick motors or stages by simply increasing the Agena propellant load by using optional strap-on-tanks. The primary objective of the study is to define those changes to the Agena required for it to function in the reusable mode in the 100 percent capture of the NASA-DOD mission model. The application of the existing Agena vehicle as a reusable upper stage for the space shuttle is discussed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |